Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.
Melanie Senior
A few years ago, the talk at Novo Nordisk AS was of diversifying away from insulin and diabetes. Today, though, as the world’s leading producer of insulin in volume...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
